EVora is building a vesicle-based delivery platform that lets biological medicines be swallowed rather than injected, drawing on both natural extracellular vesicles and synthetic lipid vesicles modelled on them.
Biological drugs such as insulin break down in the gut and are poorly absorbed. Today, injection is the only option for most of them.
Extracellular vesicles (EVs) are nanoscale lipid particles that cells use to carry molecular cargo. Some, such as those in milk, evolved to survive digestion and cross the gut. EVora works across two complementary vesicle families to turn that biology into a drug-delivery platform.
Vesicles isolated from milk that are naturally adapted to the gastrointestinal tract.
Engineered lipid vesicles designed using what we learn from natural EVs: their membrane composition, surface features and gut behaviour.
One design philosophy, two carrier routes. We choose the vesicle that best fits each payload and indication.
Vesicles shield biologics from harsh gastric conditions and digestive enzymes.
They cross the mucus layer and interact with the epithelium, enhancing uptake and transport at the gut wall.
They can cross the epithelial barrier to deliver the payload locally or into systemic circulation.
The same core platform, engineered for each payload and indication.
Natural milk EVs or synthetic EV-inspired vesicles
Biologics loaded into the vesicle
Lipid and ligand modification tunes stability, targeting and release
Off-the-shelf capsules, swallowed: no injection needed
Cargo released systemically or at the disease site
A lead programme in oral biologics, with two follow-on applications built on the same carrier technology.
EVora is at a pre-incorporation stage, preparing to spin out of King's College London. We are opening conversations with investors who want to help take an oral biologics platform, already validated by competitive non-dilutive funding, towards the clinic.
An early entry point into a platform company with established IP, formulation know-how and three programmes built on one carrier platform.
Spin-out from King's College London
Non-dilutive funding from UKRI, Wellcome Leap and Sanofi
Plus siRNA / mRNA formulations
Licences, milestones and royalties
Non-dilutive funding already validates the platform.
Supports core platform engineering, with a focus on oral RNA delivery.
Backs translational development of microbiome-sparing oral antibiotic delivery.
Industry validation from a global pharmaceutical company.
Market size in 2025 versus forecast, US$ billions.
Oral and systemic antibiotics market (2025), with ~$2–7B potentially replaceable by microbiome-sparing approaches
Forecast growth in every segment (1.8× to 2.2×) by 2030–2034
Sources: MarketsandMarkets (oral proteins and peptides); Research and Markets (IBD treatment); IMARC (oral antibiotics); Custom Market Insights (iron supplements). Figures as cited in each report.
Three commercial programmes, each with a partner-led model.
| Programme | What we sell | Why partners buy | Commercial model |
|---|---|---|---|
| EVora PharmaPeptides, proteins, antibodies, RNA, vaccines | Oral delivery platform | Turn injectable or poorly absorbed drugs into oral products | Research collaboration, licence, milestones and royalties |
| EVora Anti-InfectiveMicrobiota-sparing antibiotics | Targeted, microbiota-sparing delivery | Improve targeting and reduce collateral microbiome disruption | Co-development or licence |
| EVora NutritionPoorly absorbed micronutrients, e.g. iron and zinc Potential fast lane | Enhanced micronutrient delivery | Improve absorption and potentially reduce dose and GI effects | Ingredient licence or B2B partnership |
We welcome conversations with investors and strategic partners ahead of incorporation. Get in touch with the founders to request the full investor deck.
King's College London expertise in drug delivery, nanomedicine and translational science.
Expert in oral drug delivery and mucosal biology; leads platform development of vesicle-based oral carriers.
Specialist in nanomedicine and targeted drug delivery; drives formulation and ROS-responsive lipid engineering.
Co-founders hold academic appointments at King's College London.
For investment, partnership or research collaboration enquiries, please contact Driton Vllasaliu or Maya Thanou at King's College London.